Skip to main content
SpringerLink
Log in

Fortschritte in der Behandlung des oberflächlichen Harnblasenkarzinoms mit BCG-Immuntherapie — Ergebnisse kontrollierter nordamerikanischer Studien

  • Conference paper
BCG-Therapie des oberflächlichen Harnblasenkarzinoms

  • 17 Accesses

Zusammenfassung

In den Vereinigten Staaten ist während des vergangenen Jahrzehnts die Inzidenz von Blasenkarzinom um 36% angestiegen, während die Sterblichkeitsrate trotz dieses Anstiegs um 8% zurückging (Boring et al. 1993). Zu den signifikantesten Veränderungen bei der Behandlung des oberflächlichen Blasenkarzinoms zählt die in diesem Zeitraum eingeführte und immer öfter verwendete intravesikale BCG-Immun-therapie. Nach Morales Bericht über eine reduzierte Tumorhäufigkeit nach BCG-Therapie bestätigten wir als erste die Vorteile dieser Behandlungsmethode in einer kontrollierten klinischen Studie (Lamm et al. 1980). In zahlreichen weiteren kontrollierten Studien wurden seitdem sowohl die Wirksamkeit der intravesikalen BCG-Therapie bestätigt, als auch zusätzliche signifikante Verbesserungen der schon ursprünglich hocheffektiven Behandlungsmethode vorgenommen. Während des letzten Jahrzehnts war die Southwest Oncology Group (SWOG) besonders aktiv auf diesem Gebiet tätig und konnte 3 umfangreiche, kontrollierte Studien abschließen, die dazu beitrugen, die Rolle der BCG-Immuntherapie zu bestimmen und die Behandlungsergebnisse zu verbessern.

Übersetzung aus dem Engl. von Judith Carlen-Stief.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Badalament RA, Herr HW, Wong GY et al. (1987) A prospective, randomized trial of maintenance versus nonmaintenance intravesical Bacillus Calmette- Guerin therapy of superficial bladder cancer. J Clin Oncol 5: 441–445

    PubMed  CAS  Google Scholar 

  • Boring CC, Squires TS, Tong T(1993) Cancer Statistics. CA 43: 18–19

    Google Scholar 

  • Brosman SA (1982) Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 128: 27–30

    PubMed  CAS  Google Scholar 

  • Cookson MS, Sarosdy MF (1992) Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol 148: 797–801

    PubMed  CAS  Google Scholar 

  • Debruyne FMJ, Van der Meijden APM et al. (1988) BCG-RIVM versus Mitomycin C intravesical therapy in patients with superficial bladder cancer. Urology 31 (Suppl): 20–25

    PubMed  CAS  Google Scholar 

  • Edsmyr F, Andersson L (1978) Chemotherapy in bladder carcinoma. Urol Res 6: 263–4

    Article  PubMed  CAS  Google Scholar 

  • Herr HW (1992) Use of Bacillus Calmette-Guerin vaccine; Indications and results. In: Soloway MS, Paulson DF (eds) Problems in Urology: Transitional Cell Malignancy. Lippincott, Philadelphia, 6: 484–492

    Google Scholar 

  • Herr HW, Laudone VP, Whitmore WF (1987) An overview of intravesical therapy for superficial bladder tumors. J Urol 138: 1363–1368

    PubMed  CAS  Google Scholar 

  • Hudson MA, Ratliff TL, Gillen DP et al. (1987) Single course versus maintenance Bacillus Calmette-Guerin therapy for superficial bladder tumors: A prospective, randomized trial. J Urol 138: 295–298

    PubMed  CAS  Google Scholar 

  • Huland H, Otto U (1983) Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Eur Urol 9: 84–86

    PubMed  CAS  Google Scholar 

  • Jakse G, Hofstadter F, Marberger H (1981) Intracavitary doxorubicin hydrochloride therapy for carcinoma in situ for the bladder. J Urol 125: 185–90

    PubMed  CAS  Google Scholar 

  • Jauhiainen NK, Rintalla E, Alfthan O, and the Finn Bladder Group (1990) Immunotherapy (BCG) versus chemotherapy (MMC) in intravesical treatment of superficial urinary bladder cancer. In: DeKernion JB (ed) Immunotherapy of UrologicalTumors, Churchill Livingstone Edinburgh, pp 13–26

    Google Scholar 

  • Kowalkowski TS, Lamm DL (1988) Intravesical therapy of superficial bladder cancer. In: Resnick MI (ed) Current trends in urology. Williams & Wilkins, Baltimore, pp 89–107

    Google Scholar 

  • Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM (1980) Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 124: 38–42

    PubMed  CAS  Google Scholar 

  • Lamm DL (1985) Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 134: 40–47

    PubMed  CAS  Google Scholar 

  • Lamm DL, DeHaven JL, Shriver JS, Crispen R, Grau D, Sarosdy MF (1990) A randomized prospective comparison of oral versus intravesical and percutaneous Bacillus Calmette-Guerin for superficial bladder cancer. J Urol 144: 65–67

    PubMed  CAS  Google Scholar 

  • Lamm DL (1991) Immunotherapy versus chemotherapy in the treatment of superficial bladder tumors. In: Alderson AR, Oliver ARD, Hannim IW, Bloom HJG (eds) Urologie Oncology: Dilemmas and Developments. Wiley, Chichester, pp 107–117

    Google Scholar 

  • Lamm DL, DeHaven JL, Shriver J, Sarosdy MF (1991a) Prospective randomized comparison of intravesical versus intravesical plus percutaneous Bacillus Calmette-Guerin in superficial bladder cancer. J Urol 145: 738–40

    PubMed  CAS  Google Scholar 

  • Lamm DL, Blumenstein BA, Crawford ED et al. (1991b) A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. New Engl J Med 325:1205–1209

    Article  PubMed  CAS  Google Scholar 

  • Lamm DL, Crawford ED, Blumenstein B et al. (1992) Maintenance BCG immunotherapy of superficial bladder cancer: a randomized prospective Southwest Oncology Group Study. J Urol 147: 4(242)

    Google Scholar 

  • Lamm DL, Crawford ED, Blumenstein B et al. (1993) SWOG 8795: Arandom- ized comparison of bacillus Calmette-Guerin and Mitomycin C prophylaxis in stage Ta andTl transitional cell carcinoma of the bladder. J Urol 149:282A (275)

    Google Scholar 

  • Martinez-Pineiro JA, Leon JJ, Martinez-Pineiro L Jr et al. (1990) Bacillus Calmette-Guerin versus Doxorubicin versus Thiotepa: A randomized prospective study in 202 patients with superficial bladder cancer. J Urol 143:502–506

    PubMed  CAS  Google Scholar 

  • Netto RR Jr, Lemos CG (1983) A comparison of treatment methods for prophylaxis of recurrent superficial bladder tumors. J Urol 129: 33–34

    Google Scholar 

  • Reichert DF, Lamm DL (1984) Long term protection in bladder cancer following intralesional immunotherapy. J Urol 132: 570–573

    PubMed  CAS  Google Scholar 

  • Riibben H, Graf-Dobberstein C, Ostwald R et al. (1990) Prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer; mitomycin C vs BCG Connaught vs TUR alone. In: DeKernion JB (ed) Immunotherapy of Urological Tumors, Churchill Livingstone, Edinburgh, pp 27–36

    Google Scholar 

  • Traynelis CL, Lamm DL (1991) Current status of intravesical therapy for bladder cancer. In: Rous SN (ed) Urology Annual, Vol 5. Appleton & Lange, East Norwalk

    Google Scholar 

  • Witjes JA, Van der Meijden APM et al. (1993) Randomized prospective study comparing intravesical instillations of Mitomycin C, BCG-Iice and BCG- RIVM in PTa, PT1 tumors and primary CIS of the urinary bladder. Eur J Cancer 29a: 1672–1676

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Health Sciences Center, West Virginia University, P.O. Box 9251, 26506, Morgantown, WV, USA

    D. L. Lamm

Authors
  1. D. L. Lamm
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Urologie, Medizinische Universität zu Lübeck, Ratzeburger Allee 160, D-23538, Lübeck, Deutschland

    Andreas Böhle  & Dieter Jocham  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Lamm, D.L. (1994). Fortschritte in der Behandlung des oberflächlichen Harnblasenkarzinoms mit BCG-Immuntherapie — Ergebnisse kontrollierter nordamerikanischer Studien. In: Böhle, A., Jocham, D. (eds) BCG-Therapie des oberflächlichen Harnblasenkarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78843-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78843-7_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-78844-4

  • Online ISBN: 978-3-642-78843-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation